Clinical Trials Tracker

Array BioPharma said a $5-million milestone was achieved after the start of Array’s phase 3 trial in patients with low-grade serous ovarian cancer (LGSOC). Read More ›

Pharmacyclics, a clinical-stage bio­­-pharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune-mediated diseases, has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the investigational oral Bruton’s tyrosine kinase inhibitor, ibrutinib, for 2 relapsed/refractory B-cell malignancy indications: mantle-cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

OncoGenex Pharmaceuticals, Inc, has initiated the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled phase 2 trial evaluating OGX-427, a heat shock protein 27 (HSP27) inhibitor, in patients with previously untreated, advanced, nonsquamous non–small-cell lung cancer (NSCLC). Read More ›

Page 5 of 5

Urology Practice Management logo
Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

UPM e-Newsletter
UPM print publication